Get the Stockscreener App
7.47
1.77%
0.13
Lyra Therapeutics Inc stock is traded at $7.47, with a volume of 2,802.
It is up +1.77% in the last 24 hours and down -8.90% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$7.34
Open:
$7.3
24h Volume:
2,802
Relative Volume:
0.00
Market Cap:
$12.28M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-5.0134
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
+5.96%
1M Performance:
-8.90%
6M Performance:
-27.37%
1Y Performance:
-52.05%
1-Day Range:
$7.2101
$7.5747
1-Week Range:
$6.92
$7.5747
52-Week Range:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
7.47 | 12.02M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Bollinger Bands Show Potential Breakout in Lyra Therapeutics Inc.Portfolio Update Summary & Weekly High Return Stock Forecasts - thegnnews.com
Published on: 2025-08-20 23:19:46 - classian.co.kr
Screener Results Flag Lyra Therapeutics Inc. as OversoldMarket Volume Summary & Free Expert Verified Stock Movement Alerts - newsyoung.net
Can Lyra Therapeutics Inc. maintain sales growthJuly 2025 EndofMonth & High Return Trade Guides - thegnnews.com
Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift - MSN
Building trade automation scripts for Lyra Therapeutics Inc.July 2025 PreEarnings & Low Risk High Reward Ideas - Newser
How to recover losses in Lyra Therapeutics Inc. stockEarnings Beat & Low Risk Entry Point Guides - Newser
Lyra Therapeutics Inc. Attempts Reversal From Key SupportJuly 2025 Price Swings & Risk Controlled Swing Alerts - sundaytimes.kr
Lyra Therapeutics Reports Q2 2025 Financial Results - TipRanks
Healthcare Stocks Under Analyst Spotlight: Lyra Therapeutics, Stoke Therapeutics, and Astria Therapeutics. - AInvest
Cautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects - TipRanks
What to do if you’re stuck in Lyra Therapeutics Inc.Jobs Report & Free Fast Entry Momentum Trade Alerts - Newser
Should you wait for a breakout in Lyra Therapeutics Inc.2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
Lyra Therapeutics shares rise 11.19% intraday after positive ENLIGHTEN 2 Phase 3 results and extended cash runway. - AInvest
Key metrics from Lyra Therapeutics Inc.’s quarterly dataWeekly Investment Summary & Expert Approved Trade Ideas - Newser
Chart based exit strategy for Lyra Therapeutics Inc.2025 Big Picture & High Conviction Buy Zone Picks - Newser
Why Lyra Therapeutics Inc. is moving todayMarket Sentiment Summary & Fast Momentum Stock Entry Tips - Newser
Developing predictive dashboards with Lyra Therapeutics Inc. dataShare Buyback & Free Reliable Trade Execution Plans - Newser
Lyra Therapeutics 2025 Q2 Earnings Significant Loss Reduction - AInvest
Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78) - MSN
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Risk vs reward if holding onto Lyra Therapeutics Inc.Market Risk Analysis & Reliable Price Action Trade Plans - Newser
Lyra Therapeutics Q2 2025 Earnings: Revenue of $183K Surpasses Forecast, EPS of -$5.51 Beats Estimate - AInvest
Lyra Therapeutics Posts 85% Drop in Q2 Loss, Positive LYR-210 Clinical Trial Results Position Company for Regulatory Meeting - AInvest
Lyra Therapeutics Posts 85% Q2 Loss Drop - Nasdaq
Can trapped investors hope for a rebound in Lyra Therapeutics Inc.Historical Stock Summary and ROI Review - Newser
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Lyra Therapeutics: Navigating Financial Challenges on the Road to Profitability - AInvest
Lyra Therapeutics Q2 rev. up 9% YoY, cash runway extended to 3Q 2026. - AInvest
LYRA THERAPEUTICS Earnings Results: $LYRA Reports Quarterly Earnings - Quiver Quantitative
Lyra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Using economic indicators to assess Lyra Therapeutics Inc. potentialInstitutional Holding Behavior Pattern Analysis - Newser
Lyra's Nasal Implant Shows Promise in Phase 3 Trial, Extends Cash Runway Through 2026 - Stock Titan
Real time breakdown of Lyra Therapeutics Inc. stock performanceSwing Trade Signal and Price Prediction - Newser
What makes Lyra Therapeutics Inc. stock price move sharplyPortfolio Allocation Strategy for Stability - Newser
Understanding Lyra Therapeutics Inc.’s price movementOversold Reversal Picks with Buy Zone - Newser
Sentiment analysis tools applied to Lyra Therapeutics Inc.Trade Alert System with Volume Analysis - Newser
Custom strategy builders for tracking Lyra Therapeutics Inc.Free Daily Profit Focused Stock Screener - Newser
Is Lyra Therapeutics Inc. stock reversal real or fakeBuy Strategy Review With Performance Summary - Newser
What earnings revisions data tells us about Lyra Therapeutics Inc.Smart Entry Watchlist with Daily Analysis - Newser
Chart overlay techniques for tracking Lyra Therapeutics Inc.Free Low Risk Picks for Daily Trading - Newser
Lyra Therapeutics Inc. stock trendline breakdownDaily Swing Candidate Analysis with Chart Patterns - Newser
RSI + MACD Show Convergence for Lyra Therapeutics Inc.Scalable Portfolio Growth Suggestions Released - metal.it
Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Published on: 2025-08-11 02:07:15 - Newser
Will Lyra Therapeutics Inc. rebound enough to break evenFree Short Term Trading Opportunity Watch - Newser
Predicting Lyra Therapeutics Inc. trend using moving averagesFree AI Powered High Return Stock Calls - Newser
Is it time to cut losses on Lyra Therapeutics Inc.Free AI-Powered Trade Planning with Indicators - Newser
Why Lyra Therapeutics Inc. stock attracts strong analyst attentionSafe Momentum Strategy With Trend Analysis - Newser
How to use a screener to detect Lyra Therapeutics Inc. breakoutsWeekly High Conviction Trade Setup Analysis - Newser
Is Lyra Therapeutics Inc. stock poised for growthSmart Risk Strategy with Entry Optimization - Newser
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):